1. Home
  2. Medical Research
  3. Austin, TX
  4. Happy Lungs Project

Happy Lungs Project

Happy Lungs Project has an America's Best Score of 55 out of 100, based on its 2025 Form 990, below the 60-point bar to be ranked.

  • Austin, TX
  • Tax-exempt since 2021
  • EIN: 87-0957020
happylungsproject.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
55OF 100 Not ranked Below the 60-point bar How this score is calculated

Organization summary

Happy Lungs Project is a 501(c)(3) organization, classified under Medical Research (NTEE H12). Contributions are tax-deductible.

2405 E 8Th St, Austin, TX 78702-3525

Among the 8 scored medical research organizations in Austin, Happy Lungs Project holds 47.1 months of operating reserves (peer median 44.7 months), runs a typical yearly surplus of 52.5% (peers: surplus of 22.4%), and has cut spending 22.3% a year (peers: grown spending 22.1% a year).

In fiscal year 2025 it reported $307,543 in revenue and $141,581 in expenses, with contributions making up 100.0% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Our mission is to save the lives of ret-positive lung cancer patients by advancing research and treatment options.

Main program · fiscal year 2025

  • Provide support for researchers and clinicians in finding a cure, raising awareness about testing methods for early detection of nsclc mutations, developing individualized therapies based upon new testing and diagnostics, including methods to combat development of targeted therapy resistance, determining if existing pharmaceuticals can be repurposed or combined with other treatments to provide eff… Read more

    Provide support for researchers and clinicians in finding a cure, raising awareness about testing methods for early detection of nsclc mutations, developing individualized therapies based upon new testing and diagnostics, including methods to combat development of targeted therapy resistance, determining if existing pharmaceuticals can be repurposed or combined with other treatments to provide effective, novel treatments, and developing new immunotherapies which can be used in conjunction with existing treatments, or employed as primary therapy.

    $88,981 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 63¢ went to programs, 8¢ to management and 29¢ to fundraising.

  • Programs $88,981
  • Management $12,232
  • Fundraising $40,368

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score55 / 100
DesignationNot ranked

Score breakdown

MeasureThis organizationPoints
Operating reserves (reduced: more than 3 years of cash)47.1 mo; 47.1 mo in cash21.7 / 25
Financial balance (median margin)+52.5%1.6 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth−22.3% / yr0 / 15
Track record5 years2 / 10
Debt load0.0% of assets10 / 10
Total55.4 → 55
Spending on programs
Not scored; America's Best needs 65%+
63%Below

Compared with Austin peers

MeasureThis organizationPeer median
Operating reserves47.1 mo44.7 mo
Typical margin+52.5%+22.4%
Spending growth−22.3% / yr+22.1% / yr
Debt load0.0%0.0%

Peers: the 8 Austin medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$307,543Fiscal year 20252022: $922,26520222023: $362,80220232024: $554,87820242025: $307,5432025
Expenses$141,581Fiscal year 20252022: $301,70320222023: $624,27220232024: $632,12720242025: $141,5812025
Total assets$555,190Fiscal year 20252022: $727,94820222023: $466,47720232024: $389,22820242025: $555,1902025
Total liabilities$0Fiscal year 20252022: $020222023: $020232024: $020242025: $02025
Fiscal year ending December 2025
Revenue$307,543
Expenses$141,581
Net income$165,962
Net assets$555,190

Notable sources of revenue

Percent of total revenue
Contributions$307,543
Program services$0
Investment income$0
Other (net)$0

Assets / debt

Total assets$555,190
Total liabilities$0
Net assets$555,190

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$554,878
Expenses$632,127
Net income−$77,249
Net assets$389,228

Notable sources of revenue

Percent of total revenue
Contributions$554,878
Program services$0
Investment income$0
Other (net)$0

Assets / debt

Total assets$389,228
Total liabilities$0
Net assets$389,228

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$362,802
Expenses$624,272
Net income−$261,470
Net assets$466,477

Notable sources of revenue

Percent of total revenue
Contributions$362,802
Program services$0
Investment income$0
Other (net)$0

Assets / debt

Total assets$466,477
Total liabilities$0
Net assets$466,477

Compensation

Officers and key employees$0
Share of expenses0.0%
Fiscal year ending December 2022
Revenue$922,265
Expenses$301,703
Net income$620,562
Net assets$727,948

Notable sources of revenue

Percent of total revenue
Contributions$922,265
Program services$0
Investment income$0
Other (net)$0

Assets / debt

Total assets$727,948
Total liabilities$0
Net assets$727,948

Compensation

Officers and key employees$0
Share of expenses0.0%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?